Guardian Pharmacy Services Inc. Class A Common Stock (GRDN)

FairStock Score: 55/100 — STEADY

Key Financials

Strengths

• Generates $74 million in annual free cash flow (3.1% yield on market cap)
• Strong Piotroski F-Score of 7/9 indicating robust financial health across profitability, leverage, and efficiency metrics
• High return on equity of 26.6% demonstrating efficient capital deployment
• Conservative balance sheet with debt-to-equity of just 0.21, providing financial flexibility
• Altman Z-Score of 8.9 confirms minimal bankruptcy risk and strong solvency

Concerns

• Trades significantly above Graham Number ($8) with negative 387% margin of safety—limited downside protection

AI Analysis

Guardian Pharmacy Services Inc. Class A Common Stock is a small-cap healthcare company valued at $2.4 billion. The business generates $1.4 billion in annual revenue with a 1.4% net margin and $74 million in free cash flow. From a quality standpoint, Guardian shows solid Piotroski F-Score of 7/9 and Altman Z-Score of 8.9 confirms fortress-level solvency. On valuation, the stock is commanding a steep 47.4x multiple, with trades far above its Graham Number ($8) with no margin of safety. Growth dynamics show revenue growing at 17.4% and profit growth of 75.2%. Our composite FairStock Score of 55/100 reflects mixed fundamentals overall. Investors should weigh the business quality against the current price and their own margin of safety requirements.

Bull Case

Guardian's 17% revenue growth trajectory could accelerate as it captures additional market share in the healthcare sector. With $74 million in annual free cash flow (3.1% yield), management has ample capital for buybacks, dividends, or accretive acquisitions.

Bear Case

At 47x earnings, any growth disappointment triggers rapid multiple compression—a 20% earnings miss plus multiple contraction to 20x implies 40%+ downside. Regulatory changes, input cost inflation, or demand normalization represent underappreciated risks that could materially impact forward estimates.

Data from SEC filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer